FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and concerns a formulation for treating skin damages containing a therapeutic agent and an ointment base. The therapeutic agent is presented by a microbial cell suspension of nonpathogenic plasmid-free strain E. coli, producing human recombinant peroxiredoxin 6 identical in an amino acid sequence to natural protein. The ointment base contains Vaseline, lanoline, normal saline and phenol as a preserving agent.
EFFECT: invention provides the active skin penetration of the ingredient of the therapeutic agent that enhances the therapeutic action and reduces the length of treatment.
3 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT INTERNALIN B 321, OBTAINED USING ESCHERICHIA COLI STRAIN | 2018 |
|
RU2688422C1 |
| OPHTHALMIC OINTMENT FORMULATION AND METHOD FOR PREPARING SAME | 2012 |
|
RU2531937C2 |
| OINTMENT FOR TREATING SUPERFICIAL THERMAL BURNS | 2016 |
|
RU2612260C1 |
| DOSAGE FORM CONTAINING HUMAN ALBUMIN AS ACTIVE INGREDIENT | 2023 |
|
RU2805924C1 |
| WOUND-HEALING BIOPREPARATION AS GEL | 2006 |
|
RU2322996C2 |
| BACTERIAL COLLAGENASE-BASE PHARMACEUTICAL COMPOSITION | 2000 |
|
RU2166950C1 |
| WOUND HEALING DRUG | 2022 |
|
RU2789196C1 |
| OINTMENT FOR THE TREATMENT OF BURNS AND INFECTED WOUNDS AND A METHOD FOR TREATMENT WITH ITS USE | 2021 |
|
RU2778778C1 |
| RECOMBINANT PLASMID DNA pET23-a(+)/PrxVIhumΔ178, ENCODING N-TERMINAL FRAGMENT OF HUMAN PEROXIREDOXINE VI, AND E.coli STRAIN BL21/DE3/pET23-a(+)/PrxVIhumΔ178 AS PRODUCER OF N-TERMINAL FRAGMENT OF HUMAN PEROXIREDOXINE VI | 2003 |
|
RU2250262C1 |
| COMPOSITION AND METHOD FOR PREPARING CIPROFLOXACIN OPHTHALMIC OINTMENT | 2006 |
|
RU2317810C1 |
